Cancer nanomedicine meets immunotherapy: opportunities and challenges

Qingxue Sun, Xiangyang Bai, Alexandros Marios Sofias, Roy van der Meel, Eduardo Ruiz-Hernandez, Gert Storm, Wim E. Hennink, Bruno De Geest, F. Kiessling, Hai-jun Yu, Twan Lammers (Corresponding author), Yang Shi (Corresponding author)

Research output: Contribution to journalReview articleAcademicpeer-review

1 Citation (Scopus)

Abstract

Cancer nanomedicines have shown promise in combination immunotherapy, thus far mostly preclinically but also already in clinical trials. Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle, via potentiating key steps in the immune reaction cascade, namely antigen release, antigen processing, antigen presentation, and immune cell-mediated killing. Combination nano-immunotherapy can be realized via three targeting strategies, i.e., by targeting cancer cells, targeting the tumor immune microenvironment, and targeting the peripheral immune system. The clinical potential of nano-immunotherapy has recently been demonstrated in a phase III trial in which nano-albumin paclitaxel (Abraxane®) was combined with atezolizumab (Tecentriq®) for the treatment of patients suffering from advanced triple-negative breast cancer. In the present paper, besides strategies and initial (pre)clinical success stories, we also discuss several key challenges in nano-immunotherapy. Taken together, nanomedicines combined with immunotherapy are gaining significant attention, and it is anticipated that they will play an increasingly important role in clinical cancer therapy.
Original languageEnglish
Pages (from-to)954-958
Number of pages5
JournalActa Pharmacologica Sinica
Volume41
Issue number7
Early online date17 Jun 2020
DOIs
Publication statusPublished - Jul 2020

Keywords

  • clinical translation
  • combination therapy
  • immunotherapy
  • nanomedicine
  • targeting

Fingerprint Dive into the research topics of 'Cancer nanomedicine meets immunotherapy: opportunities and challenges'. Together they form a unique fingerprint.

  • Cite this

    Sun, Q., Bai, X., Sofias, A. M., van der Meel, R., Ruiz-Hernandez, E., Storm, G., Hennink, W. E., De Geest, B., Kiessling, F., Yu, H., Lammers, T., & Shi, Y. (2020). Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacologica Sinica, 41(7), 954-958. https://doi.org/10.1038/s41401-020-0448-9